• Explore /
  • Poster
  • / Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.

Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.

Abstract Poster

Authors

null

Paul Swiecicki

University of Michigan Medical School, Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, MI

Paul Swiecicki , Yuefen Tang , Alexander T. Pearson , Jameel Muzaffar , Mary J. Fidler , Robert Winkler , Tommy Fu , Mingyu Li , Mohammad Ahmad , Dajun Yang , Yifan Zhai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT03781986

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS6094)

DOI

10.1200/JCO.2021.39.15_suppl.TPS6094

Abstract #

TPS6094

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Kathleen N. Moore

First Author: Christopher J. Hoimes

First Author: Danny Rischin

First Author: John Paul Y.C. Shen